Welcome to our dedicated page for Vicarious Surgical SEC filings (Ticker: RBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vicarious Surgical Inc. (RBOT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public surgical robotics and medical device developer. These filings offer detailed information on the Vicarious Surgical System, the company’s operating expenses, capital structure, governance and listing status.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, Vicarious Surgical presents audited and interim financial statements, segment information for research and development, sales and marketing, and general and administrative activities, along with risk factors and management’s discussion of its development-stage business. Current reports on Form 8-K disclose material events such as registered direct offerings and private placements of common stock and warrants, at-the-market offering agreements, cash burn guidance, board and committee changes, and special meetings of stockholders to approve warrant exercises under New York Stock Exchange rules.
Filings also document listing and registration matters. For example, a Form 25 filed by the New York Stock Exchange relates to the removal from listing and registration of Vicarious Surgical’s publicly traded warrants, while separate 8-K items describe the NYSE’s notice to commence delisting proceedings for those warrants and the continued listing of the company’s Class A common stock under the symbol RBOT, subject to compliance with NYSE standards.
On Stock Titan, these documents are supplemented by AI-powered summaries that explain the key points of lengthy filings, such as complex financing terms, warrant structures, or at-the-market programs. Users can quickly see highlights from 10-K and 10-Q reports, understand the implications of Form 8-K events, and review proxy materials like definitive proxy statements (DEF 14A) that cover special meetings and stockholder proposals. The page also links to information about warrants, capital raises and other securities-related disclosures, helping investors and researchers analyze how Vicarious Surgical funds and governs the development of its single-port robotic surgery platform.
Vicarious Surgical Inc. (RBOT) – Form 4 insider transaction
The filing discloses that Adam David Sachs, the company’s Chief Executive Officer, Director and >10% shareholder, executed a single sale of Class A common stock on 06/23/2025. A total of 279 shares were sold at a weighted-average price of $7.7996 per share. The transaction was carried out specifically to satisfy tax-withholding obligations arising from the vesting of restricted stock units granted on 11/23/2021.
Following the disposition, Sachs’ direct beneficial ownership stands at 50,444 Class A shares. No derivative security activity was reported in Table II. The filing states that the price represents an average of multiple trades executed between $7.62 and $7.90; full trade-level detail is available to the SEC or shareholders upon request.
Key contextual points for investors:
- The sale represents less than 1% of Sachs’ reported holdings, indicating a de-minimis impact on his ownership stake.
- The transaction is classified under code “S” (open-market sale) but is explicitly tied to tax withholding and therefore does not necessarily signal a change in sentiment.
- No other transactions, option exercises, or new awards were reported in the filing period.
Overall, the Form 4 reflects a routine administrative sale rather than a strategic reduction, and it is unlikely to materially affect the company’s governance or shareholder structure.
Sammy Khalifa, Chief Technology Officer, Director, and 10% Owner of Vicarious Surgical (RBOT), reported a tax-related transaction on June 23, 2025. The insider sold 223 shares of Class A Common Stock at a weighted average price of $7.8145 per share (ranging from $7.62 to $7.885).
Key details of the transaction:
- The sale was specifically executed to cover tax withholding obligations related to the vesting of restricted stock units originally granted on November 23, 2021
- Following the transaction, Khalifa maintains direct ownership of 35,407 shares
- The transaction was reported through Form 4 filed on June 24, 2025
This insider transaction appears to be a routine tax-related sale rather than a discretionary trading decision, as it was triggered by RSU vesting obligations.
Form 144 Notice of Proposed Sale filed by Vicarious Surgical (NYSE: RBOT) on June 28, 2025, detailing insider stock transactions. An insider plans to sell 279 shares of Class A Common Stock through UBS Financial Services, with an aggregate market value of $2,226.42. The total outstanding shares are 5,277,994.
The securities were originally acquired through a Restricted Stock Lapse of 812 shares on June 20, 2025. The seller, Adam Sachs, has conducted two previous sales in the past 3 months:
- May 20, 2025: 817 shares for $5,961 gross proceeds
- June 3, 2025: 463 shares for $3,210 gross proceeds
The filing indicates the seller has no knowledge of undisclosed material adverse information regarding the company's operations. The planned sale is scheduled for approximately June 23, 2025.
Vicarious Surgical (NYSE: RBOT) insider filing reveals planned sale of 223 shares of Class A Common Stock with an aggregate market value of $1,779.54. The sale is scheduled for June 23, 2025, through UBS Financial Services.
The shares being sold were acquired on June 20, 2025, through a Restricted Stock Lapse of 694 shares. The seller, who has recent trading history, previously sold:
- 653 shares on May 20, 2025 (proceeds: $4,748)
- 239 shares on June 3, 2025 (proceeds: $1,641)
The filing indicates there are 5,277,994 shares outstanding. This Form 144 represents a notice of proposed sale of securities acquired through equity compensation, demonstrating ongoing insider transactions while maintaining regulatory compliance under Rule 144 of the Securities Act.